ArticleDiscover oncology2025
Extent of reoperation predicts survival in recurrent IDH-wildtype glioblastoma based on institutional data and individual patient data meta analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GB) is the most aggressive brain tumor, characterized by rapid progression and poor prognosis. Despite initial multimodal treatment options, therapeutic options become more limited upon recurrence. Consequently, recurrent IDH-wildtype GB is associated with poor survival outcomes, with limited data to guide optimal therapeutic strategies. This study presents the largest meta-analysis to date, pooling institutional data with individual patient data (IPD), addressing progression-free survival (PFS) and overall survival (OS) from timepoint after re-resection.
methodsInstitutional data and data from literature (2016-2024) were analyzed to evaluate PFS and OS in relation to the extent of resection (EoR). Survival data from identified studies were extracted from Kaplan-Meier curves with the R package IPDfromKM. Additionally, a retrospective analysis of institutional data was conducted, assessing for PFS and OS in 53 patients. EoR was dichotomized as suggested by the RANO group into residual contrast-enhancing tumor volume (CE-RTV) ≤ 1 cm
resultsA total of 442 IPD were included in this meta-analysis. Among them, 331 patients (74.9%) underwent neurosurgical treatment with CE-RTV ≤ 1cm
conclusionAcross pooled IPD, maximal safe resection at re-resection operationalized as GTR or RANO class 1 and 2 was significantly associated with longer overall survival (OS). Where volumetric assessment is available, achieving a postoperative CE-RTV ≤ 1 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.